Salhotra Amandeep, Yuan Shan, Ali Haris
Department of Hematology and Hematopoietic Cell Transplantation (HCT), City of Hope National Medical Center, Duarte, CA, United States.
Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, City of Hope National Medical Center, Duarte, CA, United States.
Front Oncol. 2023 Aug 28;13:1196564. doi: 10.3389/fonc.2023.1196564. eCollection 2023.
In this review, we discuss recipient risk assessment for allo-HCT regarding comorbidities present at baseline to predict non relapse mortality. We further reviewed the incorporation of remission status and cytogenetic risk prior to allograft transplantation to predict relapse rates for hematologic malignancies. HCT-CI and DRI are tools available to physicians to assess the risk-benefit of allo-HCT in patients referred for transplantation. Next, we discuss our algorithm for donor selection and criteria for donor selection in case matched donors are not available. Finally, we discuss our approach for stem cell mobilization, especially in donors failing G-CSF, and our approach for the use of plerixafor and data supporting its use.
在本综述中，我们讨论了异基因造血细胞移植（allo-HCT）受者的风险评估，涉及基线时存在的合并症以预测非复发死亡率。我们还回顾了在同种异体移植前纳入缓解状态和细胞遗传学风险以预测血液系统恶性肿瘤的复发率。造血细胞移植合并症指数（HCT-CI）和疾病风险指数（DRI）是医生可用于评估转诊移植患者allo-HCT风险效益的工具。接下来，我们讨论我们的供体选择算法以及在没有匹配供体情况下的供体选择标准。最后，我们讨论我们的干细胞动员方法，特别是在对粒细胞集落刺激因子（G-CSF）无反应的供体中，以及我们使用普乐沙福的方法和支持其使用的数据。
